Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 3 (2006), Issue 12 (December)

1. Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu.
   J Clin Pathol, 59(12): 1327-30. [Abstract] [Full-text]
2. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells.
   Cancer Res, 66(23): 11247-53. [Abstract] [Full-text]
3. First--select the target: better choice of adjuvant treatments for breast cancer patients.
   Ann Oncol, 17(12): 1772-6. [Abstract] [Full-text]
4. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
   Cancer Cell, 10(6): 515-27. [Abstract] [Full-text]
5. Pharmacodynamic biomarkers for molecular cancer therapeutics.
   Adv Cancer Res, 96: 213-68. [Abstract] [Full-text]
6. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
   Anticancer Drugs, 18(1): 23-8. [Abstract] [Full-text]
7. Tumor antigens as surrogate markers and targets for therapy and vaccines.
   Adv Cancer Res, 96: 175-90. [Abstract] [Full-text]
8. A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions.
   Proc Natl Acad Sci U S A, 103(50): 19063-8. [Abstract] [Full-text]
9. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.
   Mod Pathol, 20(1): 120-9. [Abstract] [Full-text]
10. Direct detection of herceptin/trastuzumab binding on breast tissue sections.
    J Histochem Cytochem, 55(1): 25-33. [Abstract] [Full-text]
11. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.
    Mol Cancer Ther, 5(12): 3042-51. [Abstract] [Full-text]
12. A Phosphoproteomic Analysis of the ErbB2 Receptor Tyrosine Kinase Signaling Pathways.
    Biochemistry, 45(51): 15529-15540. [Abstract] [Full-text]
13. Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting.
    J Neurooncol, 81(1): 81-91. [Abstract] [Full-text]
14. Controversies in the use of adjuvant trastuzumab (Herceptin).
    J Br Menopause Soc, 12(4): 172-4. [Abstract] [Full-text]
15. Overview of the pharmacoeconomics of pharmacogenetics.
    Pharmacogenomics, 7(8): 1175-1184. [Abstract] [Full-text]
16. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
    N Engl J Med, 355(26): 2733-43. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.